Phase
Condition
Atopic Dermatitis
Eczema (Atopic Dermatitis)
Eczema (Atopic Dermatitis - Pediatric)
Treatment
CM310
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Have the ability to understand the study and voluntarily sign a written ICF.
Age ≥ 18 and ≤ 75 years old, male or female.
The fertile subjects agreed to take effective contraceptive measures throughout thestudy period.
The subjects can communicate well with the investigators and complete the follow-upaccording to the protocol.
Exclusion
Exclusion Criteria:
Live vaccine or attenuated live vaccine has been vaccinated or planned to bevaccinated within 12 weeks before randomization.
He received allergen-specific immunotherapy (desensitization therapy) within 6months before randomization.
Major surgery is planned during the study period.
Previous history of atopic keratoconjunctivitis and corneal involvement.
Other combined skin diseases that may affect the evaluation of the study.
Confronting IL-4R α Monoclonal antibody or CM310/placebo drug or ingredient allergy.
Study Design
Study Description
Connect with a study center
Hangzhou First People's Hospital
Hangzhou, Zhejiang
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.